Poorly differentiated non-small cell carcinoma NOS with a massive host inflammatory response. Credit: Yale Rosen.

China-based biopharmaceutical company Innovent Biologics has dosed the first patient in the Phase III ORIENT-11 trial designed to evaluate sintilimab (IBI308) as first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC).

The randomised, double-blinded, multicentre trial intends to study sintilimab or placebo along with pemetrexed and platinum-based chemotherapy as first-line treatment to advanced or ns-NSCLC patients in China.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial is currently treating patients with the study drug combination in four cycles, followed by a maintenance treatment of sintilimab or placebo in combination with pemetrexed until the first occurrence of disease progression, intolerable toxicity, withdrawal of consent, death, or other specified events of the trial.

Approximately 378 patients with advanced or recurrent ns-NSCLC, who have not received previous systemic anti-tumour therapy, are expected to be enrolled in the trial.

“With sintilimab entering phase III clinical trial for lung cancer, we hope to provide more treatment options for lung cancer patients in the future.”

The patients will be randomised and included in experimental and control group in a 2:1 ratio to receive the study drugs.

Out of the total patients, 252 will be included in the sintilimab group (experimental group) and 126 in the placebo group (control group).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial’s primary endpoint is progression-free survival (PFS), as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), and as assessed by an Independent Radiological Review Committee (IRRC).

Innovent founder, CEO and chairman Michael Yu said: “Lung cancer has the highest morbidity and mortality among malignant tumours in China.

“With sintilimab entering phase III clinical trial for lung cancer, we hope to provide more treatment options for lung cancer patients in the future.”

Sintilimab, a fully human anti-PD-1 antibody, has been developed by Innovent in partnership with Eli Lilly and Company in China.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact